Analysts expect that RedHill Biopharma Ltd (NASDAQ:RDHL) will report ($0.47) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for RedHill Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.45). RedHill Biopharma reported earnings of ($0.60) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 21.7%. The firm is expected to announce its next quarterly earnings results on Tuesday, July 24th.
According to Zacks, analysts expect that RedHill Biopharma will report full year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.70). For the next financial year, analysts forecast that the business will report earnings of ($1.30) per share, with EPS estimates ranging from ($1.70) to ($1.00). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover RedHill Biopharma.
RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). The firm had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.14 million. RedHill Biopharma had a negative return on equity of 114.27% and a negative net margin of 726.64%.
Several research analysts recently weighed in on RDHL shares. ValuEngine raised RedHill Biopharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. HC Wainwright set a $36.00 price target on RedHill Biopharma and gave the company a “buy” rating in a research report on Wednesday, May 9th. Finally, Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research report on Saturday, May 12th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.95.
Large investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in RedHill Biopharma during the fourth quarter valued at $110,000. ARK Investment Management LLC acquired a new position in RedHill Biopharma during the fourth quarter valued at $149,000. Citadel Advisors LLC acquired a new position in RedHill Biopharma during the fourth quarter valued at $170,000. Meitav Dash Investments Ltd. acquired a new position in RedHill Biopharma in the 4th quarter worth about $244,000. Finally, Virtu Financial LLC acquired a new position in RedHill Biopharma in the 4th quarter worth about $312,000. 20.03% of the stock is currently owned by hedge funds and other institutional investors.
RedHill Biopharma traded down $0.19, hitting $7.00, during trading hours on Thursday, MarketBeat Ratings reports. 53,804 shares of the company’s stock traded hands, compared to its average volume of 96,426. The firm has a market capitalization of $152.53 million, a price-to-earnings ratio of -2.69 and a beta of 0.80. RedHill Biopharma has a twelve month low of $4.30 and a twelve month high of $11.25.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.